{{Drugbox
| IUPAC_name = ''N''-[(1''S'')-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1''H''-indole-3-carboxamide 
| image = AB-FUBICA_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1801338-22-6
| ATC_prefix =  
| ATC_suffix =  
| PubChem =  
| smiles = O=C(N[C@H](C(N)=O)C(C)C)C1=CN(CC2=CC=C(F)C=C2)C3=CC=CC=C31
|  ChemSpiderID = 57427397
| StdInChI          = 1S/C21H22FN3O2/c1-13(2)19(20(23)26)24-21(27)17-12-25(18-6-4-3-5-16(17)18)11-14-7-9-15(22)10-8-14/h3-10,12-13,19H,11H2,1-2H3,(H2,23,26)(H,24,27)/t19-/m0/s1
| StdInChIKey       = KTVPQJSKKGZIEA-IBGZPJMESA-N


<!--Chemical data-->
| C=21 | H=22 | N=3 | O=2 | F=1
| molecular_weight = 367.42 g/mol
}}

'''AB-FUBICA''' is a drug that acts as a potent [[agonist]] for the [[cannabinoid receptor]]s, with EC<sub>50</sub> values of 21 nM at CB<sub>1</sub> and 15 nM at CB<sub>2</sub>.<ref>{{cite journal|doi=10.1021/acschemneuro.5b00112|pmid=26134475|title=Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA|journal=ACS Chemical Neuroscience|volume=6|issue=9|pages=1546|year=2015|last1=Banister|first1=Samuel D.|last2=Moir|first2=Michael|last3=Stuart|first3=Jordyn|last4=Kevin|first4=Richard C.|last5=Wood|first5=Katie E.|last6=Longworth|first6=Mitchell|last7=Wilkinson|first7=Shane M.|last8=Beinat|first8=Corinne|last9=Buchanan|first9=Alexandra S.|last10=Glass|first10=Michelle|last11=Connor|first11=Mark|last12=McGregor|first12=Iain S.|last13=Kassiou|first13=Michael}}</ref><ref name="Qian_2015">{{cite journal | url=https://link.springer.com/article/10.1007/s11419-015-0297-2 | title=Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances |author1=Zhenhua Qian |author2=Zhendong Hua |author3=Cuimei Liu |author4=Wei Jia | journal=Forensic Toxicology | year=November 2015 | doi=10.1007/s11419-015-0297-2 | pmid=26793280 | pmc=4705129 | volume=34 | pages=133â€“143}}</ref>

==See also==
* [[AB-FUBINACA]]
* [[ADB-FUBICA]]

==References==
<references/>

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Fluoroarenes]]
[[Category:Indoles]]
[[Category:Indolecarboxamides]]


{{cannabinoid-stub}}